Background: Patients who received a kidney transplant (KT) are described in literature as a group with a higher incidence of malignant neoplasms compared to the general population. Cancer development after KT has become a major issue, as a remarkable percentage of patients are diagnosed with cancer. Treatment of prostate cancer (PCa) in renal transplant recipients (RTRs) is a challenging issue that has been discussed by many authors over the years, but evidence is sparse and often includes conflicting reports. Among the therapeutic options for PCa in these patients, prostate irradiation represents a valuable alternative to surgery or other systemic therapies, as RTRs are often ineligible for these treatments.
Objective: To report six cases treated at our institution between 1998 and 2017 and discuss the available literature.
Methods: Patients' characteristics were reported along with biochemical status at diagnosis, type of immunosuppressive treatment, radiation therapy technique, and dose to transplanted kidney.
Results: Overall, prostate irradiation was delivered respecting the dose constraints and patients showed good tolerance with no reports of acute or late transplanted kidney injury.
Conclusions: Our experience confirms that prostate radiotherapy for RTRs is feasible and effective and represents a valid option that should be considered by the multidisciplinary team.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/03008916211013914 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multifunctional Nanozyme with Aptamer-Based Ratiometric Fluorescent and Colorimetric Dual Detection of Prostate-Specific Antigen.
ACS Appl Mater Interfaces
January 2025
Key Laboratory for Special Functional Aggregate Materials of Education Ministry, School of Chemistry and Chemical Engineering, Shandong University, Jinan, Shandong 250100, China.
The adsorption of DNA probes onto nanomaterials represents a promising bioassay technique, generally employing fluorescence or catalytic activity to generate signals. A significant challenge is maintaining the catalytic activity of chromogenic catalysts during detection while enhancing accuracy by overcoming the limitations of single-signal transmission. This article presents an innovative multimodal analysis approach that synergistically combines the oxidase-like activity of Fe-N-C nanozyme (Fe-NC) with red fluorescent carbon quantum dots (R-CQDs), further advancing the dual-mode analysis method utilizing R-CQDs@Fe-NC.
View Article and Find Full Text PDFProstate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants.
Prostate Cancer Prostatic Dis
January 2025
Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Background: Men with pathogenic BRCA1/2 variants are at higher risk of prostate cancer We included men with likely pathogenic/pathogenic (LP/P) variants in BRCA1/2 in a prostate-specific antigen (PSA) screening program after cascade germline testing since 2014. PSA was tested yearly and an age-specific low PSA threshold for biopsy was used, to determine if a low PSA threshold for biopsy is justified for men with pathogenic BRCA1/2 variants.
Methods: From 2014 to 2023 a total of 340 men were included in the program.
Comprehensive RNA-seq analysis of benign prostatic hyperplasia (BPH) in rats exposed to testosterone and estradiol.
Sci Rep
January 2025
Department of Urology Surgery, Guizhou Provincial People's Hospital, Guiyang, 550002, Guizhou Province, China.
The imbalance between estrogen and androgen may be an important mechanism of BPH, but the specific mechanism remains unclear. We used mixed sustained-release pellets made of testosterone and estradiol (T + E) to stimulate the establishment of a BPH rat model. Compared to the prostate hyperplasia rat model using only androgens, the new prostate hyperplasia rat model can be observed to have better macroscopic and pathological characteristics of prostate hyperplasia.
View Article and Find Full Text PDFThe Co-IMPACT Consortium: Integrating Prostate-specific Membrane Antigen Positron Emission Tomography and Radiotherapy in Prostate Cancer Care.
Eur Urol
January 2025
Department of Radiation Oncology, Medical Center - University of Freiburg Freiburg Germany; German Oncology Center, European University Cyprus Limassol Cyprus. Electronic address:
The Co-IMPACT consortium addresses knowledge gaps in prostate-specific membrane antigen positron emission tomography-guided radiotherapy for prostate cancer by establishing a global database (46 centres from 16 countries) to standardise and analyse data across four distinguished clinical scenarios. A collaborative model with the Advanced Prostate Cancer Consensus Conference aligns urgent clinical needs with actionable research insights.
View Article and Find Full Text PDFUnder-representation for Female Pelvis Cancers in Commercial Auto-segmentation Solutions and Open-source Imaging Datasets.
Clin Oncol (R Coll Radiol)
January 2025
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, USA.
Aim: Artificial intelligence (AI) based auto-segmentation aids radiation therapy (RT) workflows and is being adopted in clinical environments facilitated by the increased availability of commercial solutions for organs at risk (OARs). In addition, open-source imaging datasets support training for new auto-segmentation algorithms. Here, we studied if the female and male anatomies are equally represented among these solutions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!